Tassin Jean-Pol
Institut National de la Santé et de la Recherche Médicale Unité 114, Centre National de la Recherche Scientifique UMR 7148, Collège de France 11, Place Marcelin Berthelot, 75231 Paris Cedex 05, France.
Biochem Pharmacol. 2008 Jan 1;75(1):85-97. doi: 10.1016/j.bcp.2007.06.038. Epub 2007 Jun 30.
A challenge in drug dependence is to delineate long-term behavioral and neurochemical modifications induced by drugs of abuse. In rodents, drugs of abuse induce locomotor hyperactivity, and repeating injections enhance this response. This effect, called behavioral sensitization, persists many months after the last administration, thus mimicking long-term sensitivity to drugs observed in human addicts. Although addictive properties of drugs of abuse are generally considered to be mediated by an increased release of dopamine in the ventral striatum, recent pharmacological and genetic experiments indicate an implication of alpha1b-adrenergic receptors in behavioral and rewarding responses to psychostimulants and opiates. Later on, it was shown that not only noradrenergic but also serotonergic systems, through 5-HT(2A) receptors, were controlling behavioral effects of drugs of abuse. More recently, experiments performed in animals knockout for alpha1b-adrenergic or 5-HT(2A) receptors indicated that noradrenergic and serotonergic neurons, besides their activating effects, inhibit each other by means of the stimulation of alpha1b-adrenergic and 5-HT(2A) receptors and that this mutual inhibition vanishes in wild type mice with repeated injections of psychostimulants, opiates or alcohol. Uncoupling induced by repeated treatments with drugs of abuse installs a stable sensitization of noradrenergic and serotonergic neurons, thus explaining an increased reactivity of dopaminergic neurons and behavioral sensitization. We propose that noradrenergic/serotonergic uncoupling is a common stable neurochemical consequence of repeated drugs of abuse which may also occur during chronic stressful situations and facilitate the onset of mental illness. Drug consumption would facilitate an artificial re-coupling of these neurons, thus bringing a temporary relief.
药物依赖面临的一个挑战是描绘滥用药物所诱导的长期行为和神经化学改变。在啮齿动物中,滥用药物会诱发运动性多动,重复注射会增强这种反应。这种效应称为行为敏化,在最后一次给药后持续数月,从而模拟了在人类成瘾者中观察到的对药物的长期敏感性。尽管滥用药物的成瘾特性通常被认为是由腹侧纹状体中多巴胺释放增加介导的,但最近的药理学和遗传学实验表明,α1b-肾上腺素能受体参与了对精神兴奋剂和阿片类药物的行为和奖赏反应。后来发现,不仅去甲肾上腺素能系统,而且血清素能系统通过5-HT(2A)受体,都在控制滥用药物的行为效应。最近,对α1b-肾上腺素能或5-HT(2A)受体基因敲除动物进行的实验表明,去甲肾上腺素能和血清素能神经元除了具有激活作用外,还通过刺激α1b-肾上腺素能和5-HT(2A)受体相互抑制,并且在重复注射精神兴奋剂、阿片类药物或酒精的野生型小鼠中,这种相互抑制消失。滥用药物的重复治疗所诱导的解偶联使去甲肾上腺素能和血清素能神经元产生稳定的敏化,从而解释了多巴胺能神经元反应性增加和行为敏化。我们提出,去甲肾上腺素能/血清素能解偶联是滥用药物重复使用的常见稳定神经化学后果,这也可能发生在慢性应激情况下,并促进精神疾病的发作。药物消费将促进这些神经元的人工重新偶联,从而带来暂时的缓解。